![](https://investorshub.advfn.com/uicon/1215.png?cb=1691074180)
Wednesday, June 05, 2024 7:30:30 AM
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-001 for the potential treatment of relapsed/refractory class III or class IV lupus nephritis.
“The FDA’s decision to grant ADI-001 Fast Track Designation for lupus nephritis underscores the urgent need for new therapies for this chronic disease,” said Chen Schor, President and Chief Executive Officer of Adicet Bio. “We plan to initiate our Phase 1 clinical study in lupus nephritis later this month. With clinical data for ADI-001 in non-Hodgkin’s lymphoma demonstrating CD19+ B-cell depletion that mirrors data by autologous alpha-beta CAR T in academic clinical studies in several autoimmune diseases, we believe we are well positioned to expand our autoimmune program to address additional indications beyond lupus nephritis. We look forward to providing a comprehensive update on our autoimmune program to investors in the near term.”
Fast Track Designation is a process designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.
Recent ACET News
- Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 11:01:37 AM
- Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma • Business Wire • 07/08/2024 11:00:00 AM
- Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 06/28/2024 09:00:00 PM
- Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma • Business Wire • 06/24/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 08:11:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 08:10:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 08:06:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 08:04:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 08:03:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 08:02:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 11:01:53 AM
- Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis • Business Wire • 06/05/2024 11:00:00 AM
- Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 05/31/2024 09:41:00 PM
- Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference • Business Wire • 05/29/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:05:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:03:01 PM
- Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates • Business Wire • 05/14/2024 08:01:00 PM
- Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress • Business Wire • 05/14/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 10:09:04 AM
- Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference • Business Wire • 05/07/2024 11:00:00 AM
- Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/30/2024 09:10:00 PM
- Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting • Business Wire • 04/22/2024 08:30:00 PM
- Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference • Business Wire • 04/08/2024 11:00:00 AM
- Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 03/28/2024 09:19:00 PM
- Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress • Business Wire • 03/19/2024 08:10:00 PM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM